There are errors in the ninth and tenth sentences of the Abstract. These sentences should read: Also there was a decrease in the risk of progression (RR of PFS: 0.82 IC 0.73--0.92) compared to placebo. Conclusions: We observed significant differences in physiologic and clinically relevant outcomes such as reduction in all-cause mortality, IPF related mortality, worsening of IPF and improvement of PFS. So pirfenidone treatment should be considered not only for its benefits in pulmonary function tests but also by its clinically relevant outcomes.

There are multiple errors in the Results described below.

The third and fourth sentences of the "Progression-free Survival (PFS)" section should read: The meta-analysis includes 786 patients in intervention group and 728 in placebo group ([Fig 5](#pone.0140288.g001){ref-type="fig"}). Pirfenidone decreased the risk of progression (RR of PFS: 0.82 IC 0.73--0.92, I2:22%) compared to placebo. We rated the quality of evidence as moderate, because of indirectness.

The third sentence of the "Worsening of IPF" section should read: The meta-analysis includes 858 patients in intervention group and 763 in placebo group (Fig 7). Pirfenidone improves worsening of IPF with a RR of 0.64 (IC 0.50--0.83, I2:23%) compared to placebo.

The second sentence of the "Adverse events" section should read: The meta-analysis includes 859 patients in intervention group and 763 in placebo group (Fig 10).

There is an error in the third sentence of the fourth paragraph of the Discussion. It should read: We also observed differences in clinically relevant outcomes such as reduction in all-cause mortality, IPF related mortality, worsening of IPF and risk of progression; but no benefit on acute exacerbation of IPF.

There are errors in the fourth and fifth columns of [Table 2](#pone.0140288.t001){ref-type="table"}. Please see the corrected [Table 2](#pone.0140288.t001){ref-type="table"} here.

10.1371/journal.pone.0140288.t001

###### Summary of finding form Pirfenidone for idiopathic pulmonary fibrosis.

1: Non primary outcome from RCTs, 2: High heterogeneity; 6MWT: Six minutes walk test; RCT: Randomized controlled trial; RR: Risk ratio; CI: confidence interval
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  Outcomes                      Anticipate absolute effects (Study population) (95% CI)   Relative Effect             NO of participants       Quality of the evidence (GRADE)   
  ----------------------------- --------------------------------------------------------- --------------------------- ------------------------ --------------------------------- ---------------
  All cause-mortality           67 per 1000                                               36 per 1000 (22 to 59)      RR 0.53 (0.32 to 0.88)   1247 (3 RCTs)                     ⨁⨁⨁◯MODERATE1
  Progression free-survival     442 per 1000                                              372 per 1000 (332 to 416)   RR 0.82 (0.73 to 0.92)   1514 (4 RCTs)                     ⨁⨁⨁◯MODERATE1
  Acute exacerbation            26 per 1000                                               15 per 1000 (5 to 47)       RR 0.59 (0.19 to 1.84)   374 (2 RCTs)                      ⨁⨁◯◯LOW1,2
  Worsening of IPF              168 per 1000                                              107 per 1000 (84 to 139)    RR 0.64 (0.50 to 0.83)   1621 (5 RCTs)                     ⨁⨁⨁◯MODERATE1
  Change on 6MWT                417 per 1000                                              308 per 1000 (267 to 358)   RR 0.74 (0.64 to 0.86)   1236 (3 RCTs)                     ⨁⨁⨁⨁HIGH
  Change on aminotransferases   30 per 1000                                               68 per 1000 (40 to 115)     RR 2.26 (1.33 to 3.83)   1621 (5 RCTs)                     ⨁⨁⨁◯MODERATE1

[Fig 5](#pone.0140288.g001){ref-type="fig"} and its caption are incorrect. Please view [Fig 5](#pone.0140288.g001){ref-type="fig"} and see its complete, correct caption here.
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